Risk of developing a second primary cancer in male breast cancer survivors: a systematic review and meta-analysis.
View / Open Files
Authors
Hassan, Hend
Sofianopoulou, Eleni
Eccles, Diana
Turnbull, Clare
Antoniou, Antonis C
Publication Date
2022-09-17Journal Title
Br J Cancer
ISSN
0007-0920
Publisher
Springer Science and Business Media LLC
Type
Article
This Version
AM
Metadata
Show full item recordCitation
Allen, I., Hassan, H., Sofianopoulou, E., Eccles, D., Turnbull, C., Tischkowitz, M., Pharoah, P., & et al. (2022). Risk of developing a second primary cancer in male breast cancer survivors: a systematic review and meta-analysis.. Br J Cancer https://doi.org/10.1038/s41416-022-01940-1
Abstract
BACKGROUND: With increasing survival after cancer diagnoses, second primary cancers (SPCs) are becoming more prevalent. We investigated the incidence and site of non-breast SPC risks following male breast cancer (BC). METHODS: PubMed, Embase and Web of Science were systematically searched for studies reporting standardised incidence ratios (SIRs) for SPCs published by March 2022. Meta-analyses used the generic inverse-variance method, assuming a random-effects model. We evaluated SIRs for overall SPCs, site-specific risks, by age at BC onset, time since BC onset and geographic region. We assessed study quality using routine techniques. RESULTS: Eight population-based retrospective cohort studies were identified. SIRs ranged from 1.05 to 2.17. The summary SIR estimate was 1.27 (95% CI: 1.03-1.56, I2: 86%), and there were increased colorectal (SIR: 1.29, 95% CI: 1.03-1.61), pancreatic (SIR: 1.64, 95% CI: 1.05-2.55) and thyroid (SIR: 5.58, 95% CI: 1.04-30.05) SPC risks. When an outlying study was excluded, the summary SIR for men diagnosed with BC before age 50 was 1.50 (95% CI: 1.21-1.85), significantly higher than men diagnosed at older ages (SIR: 1.14, 95% CI: 0.98-1.33). CONCLUSIONS: Male BC survivors are at elevated risks of developing second primary colorectal, pancreatic and thyroid cancers. The estimates may assist their clinical management and guide decisions on genetic testing.
Sponsorship
CRUK Catalyst Award CanGene-CanVar (C61296/A27223).
Funder references
Cancer Research UK (via Institute of Cancer Research (ICR)) (DGECATAAL)
National Institute for Health Research (IS-BRC-1215-20014)
Identifiers
External DOI: https://doi.org/10.1038/s41416-022-01940-1
This record's URL: https://www.repository.cam.ac.uk/handle/1810/339627
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk